Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study
- PMID: 7712392
Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study
Abstract
Background: Lactitol (beta-galactosido-sorbitol), a novel disaccharide analogue of lactulose, has been suggested as an alternative to lactulose in the treatment of portosystemic encephalopathy (PSE) in Western country. In order to assess its therapeutic effect and adverse reaction in PSE in the Chinese, we conducted this study.
Methods: Forty-one patients with PSE were enrolled in this study. Patients were randomly divided into 2 groups to receive lactitol (n = 21) or lactulose (n = 20) for 5 days. The doses of both drugs were adjusted to keep daily bowel movement of 2 to 3 times. The PSE index (mental state, EEG, asterixis, number connection test [NCT], and ammonia) was evaluated in each patient before and after treatment. Daily doses of lactitol and lactulose, stool frequency, and side effect were recorded.
Results: The mean dose of lactitol used was 66.3 +/- 36.4 gm and that of lactulose was 56.9 +/- 32.1 ml of lactulose. The majority of patients (37/41) gained clear consciousness after 5 days' treatment. In the lactitol group, blood ammonia, EEG, NCT, asterixis, mental status and PSE index before treatment were 208 +/- 62 micrograms/ml, 2.9 +/- 0.8, 4.0 +/- 0.0, 2.7 +/- 1.5, 2.9 +/- 0.7 and 77.1 +/- 10.5, respectively. All parameters decreased significantly after 5 days' treatment (119 +/- 50 micrograms/ml, 1.1 +/- 1.0, 2.9 +/- 1.2, 1.7 +/- 1.1, 0.7 +/- 0.7, and 34.4 +/- 16.0, p < 0.05). The lactulose group had the similar results. However, the improvement of PSE index after therapy in the lactitol group was significantly higher than that in the lactulose group (42.7 +/- 19.3 vs 31.1 +/- 13.7, p < 0.05). In addition, more patients in the lactitol group than in the lactulose group (67% vs 20%, p = 0.003) favored the taste of their assigned drugs. No patient who received lactitol experienced any side effects; however, six patients treated with lactulose complained of meteorism and flatulence, and four complained of nausea.
Conclusions: Both lactitol and lactulose are effective in the treatment of PSE, though the effect of lactitol seems slightly superior to that of lactulose in our study. Lactitol is more acceptable to our patients due to better palatability and less side effects. Lactitol is another good alternative in the treatment of PSE.
Similar articles
-
Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.Hepatogastroenterology. 1990 Oct;37(5):524-7. Hepatogastroenterology. 1990. PMID: 2253931 Clinical Trial.
-
Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.J Hepatol. 1987 Jun;4(3):293-8. doi: 10.1016/s0168-8278(87)80537-8. J Hepatol. 1987. PMID: 3598162 Clinical Trial.
-
Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.Dig Dis Sci. 1989 Jun;34(6):823-9. doi: 10.1007/BF01540265. Dig Dis Sci. 1989. PMID: 2656134 Clinical Trial.
-
Disaccharides in the treatment of hepatic encephalopathy.Metab Brain Dis. 2013 Jun;28(2):313-20. doi: 10.1007/s11011-013-9392-4. Epub 2013 Mar 2. Metab Brain Dis. 2013. PMID: 23456517 Review.
-
Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.Metab Brain Dis. 2016 Dec;31(6):1361-1364. doi: 10.1007/s11011-016-9910-2. Epub 2016 Sep 16. Metab Brain Dis. 2016. PMID: 27638474 Free PMC article. Review.
Cited by
-
Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis.Clin Exp Gastroenterol. 2014 Jul 12;7:241-8. doi: 10.2147/CEG.S58952. eCollection 2014. Clin Exp Gastroenterol. 2014. PMID: 25050074 Free PMC article. Review.
-
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev. 2016 May 6;2016(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Cochrane Database Syst Rev. 2016. PMID: 27153247 Free PMC article.
-
Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats.World J Gastroenterol. 2005 Feb 14;11(6):908-11. doi: 10.3748/wjg.v11.i6.908. World J Gastroenterol. 2005. PMID: 15682492 Free PMC article.
-
Hepatic encephalopathy: what the multidisciplinary team can do.J Multidiscip Healthc. 2017 Mar 24;10:113-119. doi: 10.2147/JMDH.S118963. eCollection 2017. J Multidiscip Healthc. 2017. PMID: 28392702 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources